title: Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
abstract: BACKGROUND
  As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved.
  
  
  OBJECTIVE
  This article examines the evidence currently available on the efficacy and safety of dulaglutide for use in T2DM.
  
  
  METHODS
  Dulaglutide has been shown to have similar efficacy and safety to other newer GLP-1 RAs, and better glycemic control than placebo. It lowers glycated hemoglobin (A1c), fasting and postprandial glucose levels, and promotes weight loss when used as first-, second-, or third-line therapy. It has also been shown to improve β-cell function and provide cardiovascular benefits, such as lower blood pressure and improved lipid levels. Dulaglutide also has a low risk for hypoglycemia and a similar adverse effect profile to other GLP-1 RAs in the class, with transient gastrointestinal problems and potential risk for pancreatitis.
  
  
  CONCLUSIONS
  While long-term data on safety and efficacy are forthcoming, dulaglutide is positioned to be placed at the same level as other GLP-1 RAs in the class: as second-line therapy in addition to diet and exercise in those patients who cannot achieve glycemic control on monotherapy metformin. It may also be useful as first-line therapy instead of metformin.
  
  
  CONCLUSIONS
  Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class.
authors: Ambulatory Care Division, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA.
authors: Krystal L
authors: KL
authors: Edwards
authors: Ambulatory Care Division, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA.
authors: Molly G
authors: MG
authors: Minze
keywords: GLP-1 RA; glucagon-like peptide-1 receptor agonist; incretin mimetic; type 2 diabetes mellitus therapy
references: JAMA Intern Med. 2013 Apr 8;173(7):534-9
references: 23440284
references: Diabetes Care. 2014 Aug;37(8):2159-67
references: 24879836
references: Diabetes Care. 2005 May;28(5):1092-100
references: 15855572
references: Bioorg Med Chem Lett. 2013 Jul 15;23 (14 ):4011-8
references: 23743288
references: Diabetologia. 2012 Jun;55(6):1577-96
references: 22526604
references: Diabetes Res Clin Pract. 2014 Feb;103(2):269-75
references: 24485345
references: Diabetes Obes Metab. 2011 Apr;13(4):348-56
references: 21205128
references: Diabetes Obes Metab. 2011 May;13(5):418-25
references: 21251180
references: Eur J Gastroenterol Hepatol. 2013 Feb;25(2):225-31
references: 23269036
references: Diabetes Obes Metab. 2011 May;13(5):426-33
references: 21251178
references: Diabetes Care. 2011 May;34 Suppl 2:S258-63
references: 21525465
references: Diabetes Obes Metab. 2014 Jan;16(1):38-47
references: 23829656
references: Diabetologia. 2009 Oct;52(10):2046-55
references: 19688338
references: Ann Endocrinol (Paris). 2013 Dec;74(5-6):515-22
references: 23570814
references: Nat Rev Endocrinol. 2009 May;5(5):262-9
references: 19444259
references: Diabetes Care. 2014 Aug;37(8):2149-58
references: 24742660
references: BMJ. 2014 Apr 15;348:g2366
references: 24736555
references: Nat Rev Endocrinol. 2012 Dec;8(12):728-42
references: 22945360
references: Diabetes Care. 2011 Sep;34(9):2041-7
references: 21868779
references: Adv Ther. 2014 Feb;31(2):202-16
references: 24477354
references: Pharmacotherapy. 2010 Jun;30(6):609-24
references: 20500049
references: Diabetes Care. 2004 Nov;27(11):2628-35
references: 15504997
references: Diabetes Care. 2010 Feb;33(2):428-33
references: 20103558
references: Endocr Pract. 2013 Mar-Apr;19(2):327-36
references: 23598536
references: Diabet Med. 2012 Oct;29(10):1260-7
references: 22804250
references: Lancet. 2014 Oct 11;384(9951):1349-57
references: 25018121
references: Diabetes Care. 2011 Jan;34(1):90-5
references: 20929995
references: Diab Vasc Dis Res. 2012 Apr;9(2):95-108
references: 22496442
references: Diabetes Care. 2014 Aug;37(8):2168-76
references: 24842985
references: Diabetes Care. 2009 Jul;32(7):1224-30
references: 19289857